[go: up one dir, main page]

PE20120077A1 - Compuesto 5-(5-(2-(3-aminopropoxi)-6-metoxifenil)-1h-pirazol-3-ilamino) pirazin-2-carbonitrilo y sus sales como inhibidores de chk1 - Google Patents

Compuesto 5-(5-(2-(3-aminopropoxi)-6-metoxifenil)-1h-pirazol-3-ilamino) pirazin-2-carbonitrilo y sus sales como inhibidores de chk1

Info

Publication number
PE20120077A1
PE20120077A1 PE2011001140A PE2011001140A PE20120077A1 PE 20120077 A1 PE20120077 A1 PE 20120077A1 PE 2011001140 A PE2011001140 A PE 2011001140A PE 2011001140 A PE2011001140 A PE 2011001140A PE 20120077 A1 PE20120077 A1 PE 20120077A1
Authority
PE
Peru
Prior art keywords
metoxifenil
compound
pirazin
pirazol
ilamino
Prior art date
Application number
PE2011001140A
Other languages
English (en)
Inventor
Francine S Farouz
Ryan Coastsworth Holcomb
Ramesh Kasar
Steven Scott Myers
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20120077A1 publication Critical patent/PE20120077A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE AMINOPIRAZOL TAL COMO 5-(5-(2-(3-AMINOPROPOXI)-6-METOXIFENIL)-6-METOXIFENIL)-1H-PIRAZOL-3-ILAMINO) PIRAZIN-2-CARBONITRILO EN FORMA DE SAL DE ACIDO FORMICO, SAL DE CLORURO DE DIHIDROGENO, SAL DE ACIDO METANSULFONCO, UN SOLVATO DE LA SAL O EN FORMA CRISTALINA, CARACTERIZADO PORQUE SU FORMA CRISTALINA METANSULFONICO TIENE UN PATRON DE DIFRACCION EN POLVO DE RAYOS-X QUE TIENE PICOS A 2 TETHA +- 0.02= 12.64, 21.25 Y 26.15. REFERIDA TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHO COMPUESTO ES UN INHIBIDOR DE CHK1 UTIL EN EL TRATAMIENTO DE CANCER CARACTERIZADO POR DEFECTOS EN REPLICACION DE ACIDO DESOXIRIBONUCLEICO, SEGREGACION DE CROMOSOMA O DIVISION CELULAR
PE2011001140A 2008-12-17 2009-12-10 Compuesto 5-(5-(2-(3-aminopropoxi)-6-metoxifenil)-1h-pirazol-3-ilamino) pirazin-2-carbonitrilo y sus sales como inhibidores de chk1 PE20120077A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13817608P 2008-12-17 2008-12-17

Publications (1)

Publication Number Publication Date
PE20120077A1 true PE20120077A1 (es) 2012-02-06

Family

ID=42079067

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001140A PE20120077A1 (es) 2008-12-17 2009-12-10 Compuesto 5-(5-(2-(3-aminopropoxi)-6-metoxifenil)-1h-pirazol-3-ilamino) pirazin-2-carbonitrilo y sus sales como inhibidores de chk1

Country Status (37)

Country Link
EP (1) EP2379532B1 (es)
JP (1) JP5705743B2 (es)
KR (1) KR101301777B1 (es)
CN (1) CN102245597B (es)
AR (1) AR074471A1 (es)
AU (1) AU2009333433B2 (es)
BR (1) BRPI0922468A2 (es)
CA (1) CA2746423C (es)
CL (1) CL2011001463A1 (es)
CO (1) CO6382122A2 (es)
CR (1) CR20110339A (es)
CY (1) CY1113930T1 (es)
DK (1) DK2379532T3 (es)
DO (1) DOP2011000185A (es)
EA (1) EA018118B1 (es)
EC (1) ECSP11011136A (es)
ES (1) ES2401558T3 (es)
HN (1) HN2011001446A (es)
HR (1) HRP20130167T1 (es)
IL (1) IL213160A (es)
JO (1) JO2886B1 (es)
MA (1) MA32901B1 (es)
MX (1) MX2011006603A (es)
MY (1) MY156998A (es)
NZ (1) NZ593440A (es)
PA (1) PA8850801A1 (es)
PE (1) PE20120077A1 (es)
PL (1) PL2379532T3 (es)
PT (1) PT2379532E (es)
RS (1) RS52739B (es)
SG (1) SG172222A1 (es)
SI (1) SI2379532T1 (es)
TN (1) TN2011000298A1 (es)
TW (1) TWI436996B (es)
UA (1) UA101998C2 (es)
WO (1) WO2010077758A1 (es)
ZA (1) ZA201103946B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314108B2 (en) * 2008-12-17 2012-11-20 Eli Lilly And Company 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile, pharmaceutically acceptable salts thereof, or solvate of salts
JO3145B1 (ar) * 2010-11-08 2017-09-20 Lilly Co Eli مركبات مفيدة لتثبيط chk1
GB201402277D0 (en) * 2014-02-10 2014-03-26 Sentinel Oncology Ltd Pharmaceutical compounds
TWI725041B (zh) * 2015-07-23 2021-04-21 美商美國禮來大藥廠 用於治療神經母細胞瘤及/或軟組織肉瘤之chk1/2抑制劑
TWI627168B (zh) * 2015-12-07 2018-06-21 美國禮來大藥廠 (s)-乳酸鹽
KR20180081580A (ko) * 2015-12-15 2018-07-16 일라이 릴리 앤드 캄파니 암에 대한 조합 요법
SI3411036T1 (sl) * 2016-02-04 2022-03-31 Pharmaengine, Inc. 3,5-disubstituirani pirazoli, uporabni kot kontrolne točke inhibitorjev kinaze 1 (CHK1), ter njihovi pripravki in uporaba
EP3600247A1 (en) 2017-03-31 2020-02-05 Seattle Genetics, Inc. Combinations of chk1- and wee1 - inhibitors
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
CN112457306A (zh) 2019-09-06 2021-03-09 上海瑛派药业有限公司 3,5-二取代吡唑化合物作为激酶抑制剂及其应用
CN114746413B (zh) * 2019-11-29 2024-02-23 南京明德新药研发有限公司 二氮杂吲哚类衍生物及其作为Chk1抑制剂的应用
WO2021119236A1 (en) 2019-12-10 2021-06-17 Seagen Inc. Preparation of a chk1 inhibitor compound
US11564920B2 (en) 2020-11-30 2023-01-31 Sumitomo Pharma Co., Ltd. 5-heteroaryl-1H-pyrazol-3-amine derivative
CA3200498A1 (en) 2020-11-30 2022-06-02 Sumitomo Pharma Co., Ltd. 5-heteroaryl-1h-pyrazol-3-amine derivative
WO2022251502A1 (en) 2021-05-27 2022-12-01 Boundless Bio, Inc. Checkpoint kinase 1 (chk1) inhibitors and uses thereof
GB202107932D0 (en) 2021-06-03 2021-07-21 Sentinel Oncology Ltd Preparation of a CHK1 Inhibitor Compound
GB202107924D0 (en) 2021-06-03 2021-07-21 Sentinel Oncology Ltd A pharmaceutical salt
WO2023120696A1 (ja) 2021-12-24 2023-06-29 住友ファーマ株式会社 二環性骨格を有する１ｈ－ピラゾール－３－アミン誘導体
WO2023229032A1 (ja) * 2022-05-27 2023-11-30 住友ファーマ株式会社 免疫チェックポイント阻害剤に対して治療抵抗性を示すがんの治療薬
JP7546104B2 (ja) * 2022-05-27 2024-09-05 住友ファーマ株式会社 ５－ヘテロアリール－１ｈ－ピラゾール－３－アミン誘導体からなる医薬
GB202213792D0 (en) 2022-09-21 2022-11-02 Benevolentai Bio Ltd New compounds and method
GB202403910D0 (en) 2024-03-19 2024-05-01 Benovental Cambridge Ltd New processes and intermediates for pharmaceutical products

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040034038A1 (en) * 2002-08-13 2004-02-19 Goaquan Li Urea kinase inhibitors
WO2005009435A1 (en) * 2003-07-25 2005-02-03 Pfizer Inc. Aminopyrazole compounds and use as chk1 inhibitors
WO2008117050A1 (en) * 2007-03-27 2008-10-02 Astrazeneca Ab Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer
US20090270418A1 (en) * 2008-01-09 2009-10-29 Marianne Sloss Pyrazole pyrazine amine compounds as kinase inhibitors, compositions thereof and methods of treatment therewith

Also Published As

Publication number Publication date
TWI436996B (zh) 2014-05-11
EA201170834A1 (ru) 2011-12-30
AR074471A1 (es) 2011-01-19
KR101301777B1 (ko) 2013-08-30
HRP20130167T1 (hr) 2013-03-31
CN102245597A (zh) 2011-11-16
EA018118B1 (ru) 2013-05-30
CO6382122A2 (es) 2012-02-15
SI2379532T1 (sl) 2013-05-31
IL213160A0 (en) 2011-07-31
CY1113930T1 (el) 2016-07-27
WO2010077758A1 (en) 2010-07-08
ZA201103946B (en) 2012-10-31
SG172222A1 (en) 2011-07-28
RS52739B (sr) 2013-08-30
PT2379532E (pt) 2013-03-25
IL213160A (en) 2013-12-31
CN102245597B (zh) 2014-04-16
HK1160110A1 (en) 2012-08-10
DK2379532T3 (da) 2013-03-18
TW201029994A (en) 2010-08-16
AU2009333433A1 (en) 2011-06-30
JP2012512249A (ja) 2012-05-31
ES2401558T3 (es) 2013-04-22
MX2011006603A (es) 2011-09-27
MY156998A (en) 2016-04-15
CR20110339A (es) 2011-09-14
KR20110084539A (ko) 2011-07-25
PA8850801A1 (es) 2010-07-27
JP5705743B2 (ja) 2015-04-22
ECSP11011136A (es) 2011-07-29
EP2379532A1 (en) 2011-10-26
AU2009333433B2 (en) 2012-06-14
JO2886B1 (en) 2015-03-15
HN2011001446A (es) 2013-08-05
DOP2011000185A (es) 2017-12-15
PL2379532T3 (pl) 2013-07-31
CL2011001463A1 (es) 2012-01-20
MA32901B1 (fr) 2011-12-01
UA101998C2 (ru) 2013-05-27
CA2746423C (en) 2014-01-14
NZ593440A (en) 2013-02-22
TN2011000298A1 (en) 2012-12-17
CA2746423A1 (en) 2010-07-08
BRPI0922468A2 (pt) 2020-08-04
EP2379532B1 (en) 2013-02-20

Similar Documents

Publication Publication Date Title
PE20120077A1 (es) Compuesto 5-(5-(2-(3-aminopropoxi)-6-metoxifenil)-1h-pirazol-3-ilamino) pirazin-2-carbonitrilo y sus sales como inhibidores de chk1
PE20141038A1 (es) Sales de 2,3-dihidroimidazo[1,2-c]quinazolina substituida
PT2178881E (pt) Novos derivados de 6-triazolopiridazina-sulfanil benzotiazole e benzimidazole, seu método de preparação, sua aplicação como medicamentos, composições farmacêuticas e nova utilização como inibidores de met
PL415078A1 (pl) Podstawione aminotriazole przydatne jako inhibitory kwaśnej chitynazy ssaków
ATE554085T1 (de) Neue inhibitoren von glutaminylcyclase
CR11757A (es) Compuestos de triazina como inhibidores mtor y quinasa pi3
PE20121499A1 (es) Formas cristalinas de 3-(2, 6-dicloro-3, 5-dimetoxi-fenil)-1-{6-4[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
BR112015006075A2 (pt) composto cristalino, composição farmacêutica, uso do composto cristalino, hidrato cristalino do bromidrato de vortioxetina, método para a preparação do hidrato cristalino de bromidrato de vortioxetina, método para a preparação do composto cristalino e uso do hidrato cristalino de bromidrato de vortioxetina
EA201100969A1 (ru) Солевые формы органического соединения
GEP20125537B (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
EA201101618A1 (ru) Арилпиридины в качестве ингибиторов альдостеронсинтазы
MY160785A (en) Manufacturing process for pyrimidine derivatives
CL2012000310A1 (es) Compuesto derivado de 5-fluoro pirimidinona; composicion fungicida que comprende a dicho compuesto; y un metodo para el control diferencial de ataque fungico en plantas.
MX2011010675A (es) Inhibidores de la cinasa del punto de control 1 para potenciar agentes dañinos del adn.
MX385616B (es) Inhibidores de cdk
NZ594195A (en) N-acyl anthranilic acid derivative or salt thereof
ATE537175T1 (de) Neue piperazino-dihydrothienopyrimidin-derivate
EA201390347A1 (ru) Лечение заболеваний
BRPI0716069A2 (pt) composto, composiÇço farmacÊutica, e, mÉtodo para tratar um distérbio
UA107784C2 (en) Inhibitor of melanin production
PE20141380A1 (es) Imidazopiridazinas como inhibidores de quinasa akt
CY1111240T1 (el) Παραγωγα ετεροαρυλουριας χρησιμα για την αναστολη της chk1
UY31775A (es) Compuestos heterocíclicos como inhibidores de mek
WO2011103435A3 (en) Methods for forming protected organoboronic acids
BRPI0820915A2 (pt) método para expandir células tronco hematopoéticas usando composto heterocíclico

Legal Events

Date Code Title Description
FG Grant, registration